Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess Sells 4,000 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 4,000 shares of the stock in a transaction on Friday, September 10th. The shares were sold at an average price of $120.23, for a total value of $480,920.00. Following the completion of the sale, the director now owns 59,014 shares of the company’s stock, valued at $7,095,253.22. The sale was disclosed in a filing with the SEC, which is available at this link.

Robert Chess also recently made the following trade(s):

  • On Monday, July 12th, Robert Chess sold 4,000 shares of Twist Bioscience stock. The shares were sold at an average price of $125.91, for a total transaction of $503,640.00.
  • On Wednesday, June 23rd, Robert Chess sold 4,000 shares of Twist Bioscience stock. The stock was sold at an average price of $120.10, for a total transaction of $480,400.00.

Twist Bioscience stock opened at $114.08 on Wednesday. The firm has a market cap of $5.62 billion, a price-to-earnings ratio of -39.89 and a beta of 0.70. Twist Bioscience Co. has a 1 year low of $59.26 and a 1 year high of $214.07. The firm’s 50 day moving average price is $113.90 and its two-hundred day moving average price is $118.00.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.07). Twist Bioscience had a negative return on equity of 24.59% and a negative net margin of 106.59%. The firm had revenue of $35.02 million during the quarter, compared to analyst estimates of $32.43 million. During the same period in the prior year, the business posted ($0.67) EPS. The company’s revenue for the quarter was up 65.1% on a year-over-year basis. Analysts predict that Twist Bioscience Co. will post -3.11 EPS for the current fiscal year.

A number of equities analysts have issued reports on TWST shares. William Blair initiated coverage on shares of Twist Bioscience in a report on Tuesday, June 29th. They issued an “outperform” rating on the stock. The Goldman Sachs Group began coverage on shares of Twist Bioscience in a research note on Friday, June 4th. They set a “neutral” rating and a $110.00 price objective on the stock. Robert W. Baird lowered their price objective on shares of Twist Bioscience from $140.00 to $130.00 and set an “outperform” rating on the stock in a research note on Monday, August 9th. Finally, Zacks Investment Research upgraded shares of Twist Bioscience from a “sell” rating to a “hold” rating in a research note on Thursday, September 9th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $118.00.

A number of institutional investors have recently bought and sold shares of TWST. Allianz Asset Management GmbH boosted its stake in Twist Bioscience by 1,433.9% in the 1st quarter. Allianz Asset Management GmbH now owns 1,703,610 shares of the company’s stock worth $211,009,000 after purchasing an additional 1,592,545 shares during the period. Jackson Square Partners LLC boosted its stake in shares of Twist Bioscience by 19,999.0% during the 1st quarter. Jackson Square Partners LLC now owns 1,282,114 shares of the company’s stock valued at $158,802,000 after buying an additional 1,275,735 shares during the period. BlackRock Inc. boosted its stake in shares of Twist Bioscience by 15.9% during the 1st quarter. BlackRock Inc. now owns 4,054,921 shares of the company’s stock valued at $502,242,000 after buying an additional 555,917 shares during the period. Credit Suisse AG boosted its stake in shares of Twist Bioscience by 60.7% during the 1st quarter. Credit Suisse AG now owns 1,360,208 shares of the company’s stock valued at $168,474,000 after buying an additional 513,627 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its stake in shares of Twist Bioscience by 23.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,527,910 shares of the company’s stock valued at $336,844,000 after buying an additional 481,979 shares during the period. 96.88% of the stock is owned by hedge funds and other institutional investors.

About Twist Bioscience

Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. It produces synthetic biology tools such as genes, oligo pools, variant libraries, DNA data storage and NGS. The firm also produces agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage.

Further Reading: Dual Listing What You Need to Know

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.